A Phase 1 clinical trial of AST-301 in patients with HER2-positive advanced breast cancer
Latest Information Update: 06 Sep 2022
At a glance
- Drugs AST-301 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Aston Science
- 01 Sep 2022 According to an Aston Science media release, Mary L. (Nora) Disis, M.D., University of Washington is the principle investigator of the study.
- 08 Nov 2021 New trial record
- 27 Oct 2021 According to Aston Sci media release, data from this trial was presented at American Society of Clinical Oncology (ASCO) in June.